Psoriasis is a multifactorial disease classified as an immune-mediated genetic skin disorder. The condition involves a complex interaction between the innate and adaptive immune systems. Genome-wide association studies have identified the histocompatibility complex HLA-C*06:02 as being associated with early-onset and guttate psoriasis. Inflammatory cytokines such as IL1β, TNFα, IL-23, and IL-17 play crucial roles in the clinical manifestations of psoriasis, making them targets for biological drug therapies.